News Focus
News Focus
icon url

zoriden

12/01/14 10:20 AM

#26653 RE: zb19812013 #26646

The validation of Merck is more than enough IMO for the institutes to take long positions.I can't imagine many people passing this up being at the fore front of immunotherapy. Especially at .60